Cassava Sciences (SAVA) Stock Rockets On Alzheimer’s Disease Data

Cassava Sciences SAVA Stock News

Cassava Sciences Inc (NASDAQ: SAVA) is making a run for the top in the market this morning, and for good reason. The company released the final results from a Phase 2b study, providing a source of excitement for the future. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

SAVA Announces Positive Clinical Data

In the press release, Cassava Sciences provided the results of a Phase 2b study surrounding its lead candidate sumifilam. The treatment is being developed as a potential therapeutic option for patients with Alzheimer’s disease.

The Phase 2b trial was funded by the National Institutes of Health, and resulted in significant results. The study showed that sumifilam significantly improved an entire panel of validated biomarkers of disease in patients with Alzheimer’s.

This is proof of an amazing breakthrough. SAVA explained that the ability to improve multiple biomarkers from distinct biological pathways with one drug has never been show before in Alzheimer’s disease. This is done through this new class of drug compounds that is capable of binding to a protein known as Filamin A.

The company went on to say that full study results are expected to be published in a peer-reviewed publication. In a statement, Nadav Friedmann, PhD, MD, CMO at SAVA, had the following to offer:

The clinical data suggest sumifilam may be slowing disease progression in Alzheimer’s patients. This exciting possibility will need to be evaluated in future collaborations with patients, physicians, advisors and others.

The above statement was followed up by Remi Barbier, Chairman, President & CEO of the company. Here’s what he had to say:

Other than a few drugs to help ease the decline, there’s really nothing out there to treat people with Alzheimer’s. The improvement on multiple biomarkers in this clinical study is a first and offers hope that sumifilam has potential to become a transformative treatment for people with Alzheimer’s disease.

This News Is Huge

With the positive results from the Phase 2b study in mind, the next step for the company will be to move forward with a pivotal Phase 3 trial, then off to seek approval. Should this be the case, and the data continue to be positive, the opportunity here is absolutely massive.

By 2025, it is expected that the Alzheimer’s disease treatment market will grow to be well over $10 billion per year. With few treatments on the market, all of which lack efficacy, if this treatment continues to do this well, it could quickly become the standard of care. That’s an opportunity for Cassava Sciences to drive billions of revenue through the doors per year.

Not bad for a company with a market cap of under $100 million.

All in all, considering the data released this morning, SAVA is a stock that’s well worth adding to the watchlist.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.